In October 2019, the CLDF NASH Hepatology Leadership Forum convened experts in the field of NASH, clinical trials, advocacy, policy, therapeutics and biomarker development as well as regulatory bodies to discuss challenges and opportunities to identify robust endpoints and trial designs for biomarker and drug development in the field of NASH and NASH-related fibrosis. This meeting brought world-renowned experts to the table to bridge the knowledge gaps in the field of NASH in order to move the field forward. In several plenary sessions, faculty led interactive reviews of the latest data for noninvasive diagnostic tools (biomarkers and imaging). A working group was formed and tasked with creating straight-forward practical diagnosis and staging decision trees/algorithms for primary care and non-hepatology specialists that can be made readily available as a "living" web-based resource, for providers.